Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDeate-Esophageal01 trial of ifinatamab deruxtecan in previously treated advanced or metastatic esophageal squamous cell carcinoma
CTR20250583Phase 3Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ifinatamab deruxtecan in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Overall survival. Started Sep 2025; status: active.
02
Drugs
ifinatamab deruxtecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20250583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250583.